Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
CARA Cara Therapeutics, Inc. weekly Stock Chart
CARA [NASD]
Cara Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.39 Insider Own2.20% Shs Outstand46.43M Perf Week-2.74%
Market Cap758.67M Forward P/E- EPS next Y-2.40 Insider Trans-12.09% Shs Float42.45M Perf Month-2.39%
Income-98.40M PEG- EPS next Q-0.66 Inst Own67.10% Short Float12.65% Perf Quarter-15.47%
Sales20.90M P/S36.30 EPS this Y-99.70% Inst Trans0.60% Short Ratio7.22 Perf Half Y-37.80%
Book/sh4.76 P/B3.43 EPS next Y5.90% ROA-50.80% Target Price31.89 Perf Year8.79%
Cash/sh4.16 P/C3.93 EPS next 5Y- ROE-70.30% 52W Range14.10 - 27.55 Perf YTD1.43%
Dividend- P/FCF- EPS past 5Y-22.60% ROI-57.60% 52W High-40.69% Beta2.26
Dividend %- Quick Ratio4.20 Sales past 5Y2.40% Gross Margin- 52W Low15.89% ATR0.69
Employees55 Current Ratio4.20 Sales Q/Q13.70% Oper. Margin- RSI (14)42.40 Volatility4.76% 4.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-44.60% Profit Margin- Rel Volume1.35 Prev Close16.34
ShortableYes LT Debt/Eq0.00 EarningsFeb 04 AMC Payout- Avg Volume743.84K Price16.34
Recom1.70 SMA201.50% SMA50-11.11% SMA200-19.82% Volume0 Change0.00%
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Aug-08-18Reiterated Stifel Buy $22 → $26
Jun-28-18Reiterated H.C. Wainwright Buy $24 → $26
Mar-12-18Resumed H.C. Wainwright Buy $22
Feb-12-18Upgrade Janney Neutral → Buy
Jan-19-18Initiated Seaport Global Securities Buy $27
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Mar-10-17Reiterated Laidlaw Buy $17 → $20
Oct-13-16Initiated H.C. Wainwright Buy $20
Aug-08-16Reiterated Needham Buy $27 → $23
Feb-29-16Reiterated Laidlaw Buy $30 → $17
Jan-15-20 05:26PM  New Cannabis Products Which Could Disrupt the Industry in 2020 Investopedia
Jan-08-20 04:01PM  Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-19 09:32PM  Was Smart Money Right About Piling Into Cara Therapeutics Inc (CARA) in September? Insider Monkey
Dec-06-19 04:01PM  Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan GlobeNewswire
07:20AM  Edited Transcript of CARA earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Dec-04-19 10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
07:14AM  Investors Who Bought Cara Therapeutics (NASDAQ:CARA) Shares Three Years Ago Are Now Up 78% Simply Wall St.
Dec-03-19 04:01PM  Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire -34.56%
08:41AM  Benzinga Pro's Top 6 Stocks To Watch For Tues., Dec. 3, 2019: CARA, VRAY, LE, KOD, FXI, ROKU Benzinga
07:35AM  UPDATE: Cara Therapeutics announces positive results in trial of treatment for chronic kidney disease MarketWatch
07:00AM  Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus GlobeNewswire
Nov-26-19 10:01AM  Top Marijuana Stocks for December 2019 Investopedia
Nov-13-19 09:12AM  Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock? Zacks
Nov-12-19 04:01PM  Cara Therapeutics to Present at November Investor Conferences GlobeNewswire
Nov-11-19 07:00AM  Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA Injection) KALM-1 Phase 3 Trial Results in the New England Journal of Medicine GlobeNewswire
Nov-05-19 06:35PM  Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Cara Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-01-19 07:00AM  Cara Therapeutics Announces Presentations at Kidney Week 2019 GlobeNewswire
Oct-29-19 04:40PM  Heres What Hedge Funds Think About Cara Therapeutics Inc (CARA) Insider Monkey
04:01PM  Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019 GlobeNewswire
10:32AM  Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-26-19 06:01PM  Top Marijuana Stocks on the NASDAQ Investopedia
Oct-20-19 08:45AM  Have Insiders Been Selling Cara Therapeutics, Inc. (NASDAQ:CARA) Shares? Simply Wall St.
Oct-14-19 07:00AM  Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus GlobeNewswire
Oct-01-19 02:23PM  First cannabis cafe in the U.S. opens in Los Angeles Yahoo Finance Video
Sep-26-19 04:01PM  Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire -5.89%
Sep-19-19 10:11AM  How Much Of Cara Therapeutics, Inc. (NASDAQ:CARA) Do Institutions Own? Simply Wall St.
Aug-21-19 04:24PM  Cara Therapeutics Inc (CARA) Q2 2019 Earnings Call Transcript Motley Fool
11:44AM  10 Marijuana Stocks That Could See 100% Gains, If Not More InvestorPlace
07:04AM  Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA PR Newswire
07:00AM  Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology GlobeNewswire
Aug-19-19 12:34PM  Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Pay Reflect Performance? Simply Wall St.
Aug-14-19 10:54AM  Edited Transcript of CARA earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-05-19 10:21AM  Here's Why Cara Therapeutics Rose 11.3% in July Motley Fool
07:21AM  Only These 9 Cannabis Stocks Rose in July Motley Fool
Jul-31-19 04:01PM  Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019 GlobeNewswire
Jul-29-19 04:01PM  Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-26-19 09:18PM  Weekly Cannabis Stock News: Auxly's Surprise Strategic Partner Investment Motley Fool
Jul-25-19 11:59AM  Cara Therapeutics Floats New Stock Issue Motley Fool -13.40%
Jul-24-19 08:42PM  Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock GlobeNewswire
04:01PM  Cara Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
Jul-22-19 07:00AM  Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment GlobeNewswire
Jul-17-19 07:15PM  Cara Therapeutics Inc (CARA) CFO & Chief Strategy Officer Mani Mohindru Sold $935,775 of Shares GuruFocus.com
Jul-16-19 10:28AM  4 Strong Buy Biotechs With Big 3Q19 Catalysts TipRanks
Jul-14-19 07:30AM  3 Top Biotech Stocks to Buy for the 2nd Half of 2019 Motley Fool
Jul-13-19 07:56AM  Estimating The Fair Value Of Cara Therapeutics, Inc. (NASDAQ:CARA) Simply Wall St.
Jul-12-19 06:27PM  GuruFocus Value Idea Contest Sees 2 Winners! GuruFocus.com +6.91%
Jul-11-19 08:30AM  Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA for Pruritus in Patients with Atopic Dermatitis PR Newswire
Jul-09-19 07:00AM  Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis GlobeNewswire
Jul-02-19 07:16AM  Better Buy: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
Jun-26-19 07:00AM  Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC) GlobeNewswire
Jun-13-19 07:04PM  Understanding Medical Cannabis vs. Recreational Cannabis Stocks Investopedia
Jun-02-19 09:09AM  Is Cara Therapeutics a Buy Now? Motley Fool
Jun-01-19 10:17AM  Cara Therapeutics surges 15.7% after company announces positive late-stage data for itchiness treatment MarketWatch
May-31-19 07:00AM  Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-30-19 07:48AM  Cara Shares Up on Positive Phase III Data for Itchiness Drug Zacks
May-29-19 02:30PM  Cara Therapeutics Surges on Phase 3 Results for Itchiness Treatment TheStreet.com +19.97%
01:13PM  Stocks making the biggest moves midday: Canada Goose, Capri Holdings, General Mills & more CNBC
11:48AM  Cara Therapeutics Rallies On Positive Clinical Readout For Pruritis Drug Benzinga
11:36AM  Why Cara Therapeutics Stock Is Soaring Today Motley Fool
09:36AM  Announcing: Cara Therapeutics (NASDAQ:CARA) Stock Increased An Energizing 193% In The Last Three Years Simply Wall St.
09:02AM  Cara Therapeutics stock up 12.6% after company announces positive Phase 3 data for itchiness treatment MarketWatch
07:00AM  Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus GlobeNewswire
06:00AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
May-28-19 10:43AM  3 Strong Buy Cannabis Biotech Stocks To Know Now TipRanks
May-23-19 08:09AM  Edited Transcript of CARA earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
07:10AM  Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use InvestorPlace
May-17-19 06:00AM  3 Small-Cap Biotech Stocks You Can Buy Right Now Motley Fool
May-09-19 01:12PM  Did Hedge Funds Drop The Ball On Casa Therapeutics Inc (CARA) ? Insider Monkey
May-08-19 04:01PM  Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference GlobeNewswire
02:23PM  Cara Therapeutics Inc (CARA) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:25PM  Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.71%
05:15PM  Cara: 1Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
May-06-19 08:52AM  Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options Zacks
Apr-30-19 04:01PM  Cara Therapeutics to Announce First Quarter 2019 Financial Results on May 7, 2019 GlobeNewswire
Apr-29-19 09:30AM  Are There Cannabis Stocks in Your Portfolio? Heres the Straight Dope ETF Trends
Apr-16-19 08:30AM  CBD Company to Research Now ACCESSWIRE
Apr-14-19 02:00PM  Better Buy: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
Apr-11-19 07:50AM  Cara Therapeutics Posts 2018 Revenue 15X over 2017, Questions, Catalysts, and Hurdles Every Marijuana Stock Investor Should be Considering ACCESSWIRE
Apr-09-19 08:40AM  Why Cara Therapeutics Stock Jumped 15.1% in March Motley Fool
Apr-08-19 10:00AM  3 Top Biotech Stocks to Buy in April Motley Fool
Apr-07-19 02:00PM  3 Top Small-Cap Biotech Stocks for Aggressive Investors Motley Fool
Apr-03-19 02:48PM  Edited Transcript of CARA earnings conference call or presentation 12-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Apr-02-19 04:01PM  Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire
Mar-29-19 07:20AM  Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-22-19 01:00PM  Cannabis Breakout Candidates - THC Therapeutics, Inc. (THCT) ACCESSWIRE -6.82%
Mar-13-19 01:01PM  Here's Why Cara Therapeutics Stock Rose as Much as 13.9% Today Motley Fool +11.76%
12:15PM  These Four Marijuana Stocks Are Raising Eyebrows on Wednesday ACCESSWIRE
12:19AM  Cara Therapeutics Inc (CARA) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-12-19 05:35PM  Stocks making the biggest moves after hours: Switch, Clearwater Paper and more CNBC
05:20PM  Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:27PM  Cara: 4Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
10:00AM  Top Cannabis Plays-THC Therapeutics, Inc ACCESSWIRE
Mar-07-19 08:57AM  Athersys (ATHX) Q4 Earnings: What's in Store for the Stock? Zacks
08:51AM  Is a Beat in Store for Catabasis (CATB) This Earnings Season? Zacks
Mar-05-19 04:01PM  Cara Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019 GlobeNewswire
Mar-04-19 06:41AM  Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings? Zacks
Mar-03-19 10:15AM  Better Buy: Cara Therapeutics vs. Scotts Miracle-Gro Company Motley Fool
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ives Jeffrey L.DirectorJan 02Option Exercise9.942,50024,8508,500Jan 06 06:06 PM
Ives Jeffrey L.DirectorJan 02Sale16.132,50040,3256,000Jan 06 06:06 PM
CHALMERS DEREK TPresident & CEOJan 02Sale16.0510,000160,500917,769Jan 06 06:05 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Dec 04Sale17.053,98067,85916,769Dec 04 07:52 PM
Mohindru ManiCFO & Chief Strategy OfficerDec 04Sale17.054,75581,07317,441Dec 04 07:50 PM
CHALMERS DEREK TPresident & CEODec 04Sale17.0510,699182,418927,769Dec 04 07:47 PM
Ives Jeffrey L.DirectorDec 02Option Exercise5.322,50013,3008,500Dec 04 07:49 PM
Ives Jeffrey L.DirectorDec 02Sale25.832,50064,5756,000Dec 04 07:49 PM
CHALMERS DEREK TPresident & CEODec 02Sale25.7910,000257,900918,468Dec 04 07:47 PM
Ives Jeffrey L.DirectorNov 01Option Exercise5.322,50013,3008,500Nov 05 06:21 PM
Ives Jeffrey L.DirectorNov 01Sale20.682,50051,7006,000Nov 05 06:21 PM
CHALMERS DEREK TPresident & CEONov 01Sale20.795,000103,950928,468Nov 05 06:07 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DOct 25Sale19.914,00079,64063,886Oct 29 08:36 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DOct 18Sale19.334,00077,32067,886Oct 22 05:01 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DOct 11Sale18.704,00074,80071,886Oct 16 06:26 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DOct 04Sale19.194,00076,76075,886Oct 08 04:44 PM
Ives Jeffrey L.DirectorOct 01Option Exercise5.322,50013,3008,500Oct 03 09:19 PM
Ives Jeffrey L.DirectorOct 01Sale18.212,50045,5256,000Oct 03 09:19 PM
CHALMERS DEREK TPresident & CEOOct 01Sale18.2810,000182,800933,468Oct 03 09:17 PM
Ives Jeffrey L.DirectorSep 03Option Exercise5.322,50013,3008,500Sep 05 05:37 PM
Ives Jeffrey L.DirectorSep 03Sale23.312,50058,2756,000Sep 05 05:37 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DSep 03Sale22.9220,000458,40079,886Sep 05 05:38 PM
CHALMERS DEREK TPresident & CEOSep 03Sale23.265,000116,300943,468Sep 05 05:36 PM
Ives Jeffrey L.DirectorAug 01Option Exercise5.322,50013,3008,500Aug 05 05:32 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DAug 01Sale23.2420,000464,80099,886Aug 05 05:33 PM
CHALMERS DEREK TPresident & CEOAug 01Sale23.2710,000232,700948,468Aug 05 05:31 PM
Ives Jeffrey L.DirectorAug 01Sale23.242,50058,1006,000Aug 05 05:32 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DJul 17Sale27.508,996247,390119,886Jul 19 05:47 PM
Mohindru ManiCFO & Chief Strategy OfficerJul 15Option Exercise14.0637,431526,28051,294Jul 17 05:46 PM
Mohindru ManiCFO & Chief Strategy OfficerJul 15Sale25.0037,431935,77513,863Jul 17 05:46 PM
Ives Jeffrey L.DirectorJul 01Option Exercise5.322,50013,3008,500Jul 03 04:04 PM
Ives Jeffrey L.DirectorJul 01Sale21.752,50054,3756,000Jul 03 04:04 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DJul 01Sale21.9020,000438,000128,882Jul 03 03:59 PM
CHALMERS DEREK TPresident & CEOMay 29Sale21.425,528118,410958,468May 30 06:18 PM
Terrillion ScottSec'y; Chief Compliance & G.C.May 29Sale21.382,30349,23812,416May 30 06:19 PM
Mohindru ManiCFO & Chief Strategy OfficerMay 29Sale21.392,49653,38913,863May 30 06:17 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMay 29Sale21.1911,397241,502148,882May 30 06:16 PM
Mohindru ManiCFO & Chief Strategy OfficerMar 13Option Exercise14.0616,041225,53624,067Mar 15 04:42 PM
Mohindru ManiCFO & Chief Strategy OfficerMar 13Sale19.1216,041306,7048,026Mar 15 04:42 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 13Sale18.8716,803317,073122,779Mar 14 05:13 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 12Sale17.503,19755,948139,582Mar 14 05:13 PM
CHALMERS DEREK TPresident & CEOMar 01Sale17.049,792166,856943,996Mar 05 04:53 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentFeb 28Sale17.501,50026,250142,779Mar 04 05:49 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentFeb 25Sale17.502,20038,500144,279Feb 27 05:29 PM
CHALMERS DEREK TPresident & CEOFeb 01Sale14.9920,000299,800953,788Feb 05 04:27 PM
open in yahoo | open in reuters | open in google